Harvard Bioscience
HBIO
93 hedge funds and large institutions have $177M invested in Harvard Bioscience in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 32 increasing their positions, 29 reducing their positions, and 8 closing their positions.
25% more capital invested
Capital invested by funds: $142M → $177M (+$35.4M)
10% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 29
0.04% more ownership
Funds ownership: 7.71% → 7.75% (+0.04%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less funds holding
Funds holding: 94 → 93 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$999K |
| 2 |
BlackRock
New York
|
+$773K |
| 3 |
Morgan Stanley
New York
|
+$731K |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$487K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$395K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
2C
272 Capital
Dallas,
Texas
|
-$1.46M |
| 2 |
Millennium Management
New York
|
-$1.25M |
| 3 |
Two Sigma Advisers
New York
|
-$360K |
| 4 |
Two Sigma Investments
New York
|
-$351K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$244K |
HBIO Hedge Fund Activity: Q4 2023 in Review
93 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q4 2023, worth a combined $177M — up 25% from $142M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of HBIO and 7 opened new positions — a net loss of 1 holder — while 29 trimmed existing stakes and 32 added.
The largest buyer was Portolan Capital Management, adding an estimated $999K. The largest seller was 272 Capital, cutting an estimated $1.46M.
- 93 institutional investors held Harvard Bioscience (HBIO) as of Q4 2023, down from 94 in Q3 2023.
- Funds reported $177M of Harvard Bioscience stock for Q4 2023, up 25% quarter-over-quarter.
- 7 funds opened new Harvard Bioscience positions in Q4 2023 and 8 closed out, a net change of -1 holder.
- The largest Harvard Bioscience buyer in Q4 2023 was Portolan Capital Management, an estimated $999K added.
- The largest Harvard Bioscience seller in Q4 2023 was 272 Capital, an estimated $1.46M sold.
Based on aggregated 13F filings for Q4 2023.